ESC2017

News

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.

News

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.